Clinical Outcomes of Sglt2 Inhibitors in Diabetic Patients with Heart Failure at a Tertiary Care Teaching Hospital

Background:Type 2 diabetes mellitus (T2DM) is strongly associated with cardiovascular complications, including heart failure (HF) and acute myocardial infarction (AMI). Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated cardiovascular benefits beyond glycaemic control. However, evaluation of their clinical outcomes in routine clinical practice among diabetic patients with heart failure and/or myocardial infarction remains important. The present study was undertaken to evaluate the clinical and metabolic outcomes associated with SGLT2 inhibitor therapy in diabetic patients with heart failure and/or myocardial infarction. Methodology:A prospective observational study was conducted in 59 diabetic patients with acute myocardial infarction and/or heart failure at a tertiary care hospital from October 2025 to March 2026. Patients receiving SGLT2 inhibitors were followed for three months, and changes in HbA1c, ejection fraction, NYHA class, infarct size, and lipid parameters were assessed using paired statistical tests (p < 0.05). Results:SGLT2 inhibitor therapy was associated with significant improvements in glycaemic, cardiovascular and metabolic parameters during the three-month follow-up. Mean HbA1c decreased from 8.32% to 6.98% (p < 0.001), while mean ejection fraction increased from 41.44% to 46.08% (p = 0.005). A significant improvement in NYHA functional class was observed (p < 0.001), with a shift from higher to lower functional classes. Mean infarct size decreased from 27.51% to 19.94% of left ventricular mass (p < 0.001). Significant reductions were also observed in triglycerides (167.76 to 148.97 mg/dL), VLDL (44.83 to 30.25 mg/dL), and total cholesterol (192.93 to 171.81 mg/dL), with all changes being statistically significant (p < 0.001). Conclusion:SGLT2 inhibitor therapy was associated with favorable changes in glycemic control, cardiac function, infarct size, and diabetic patients with heart failure and/or myocardial infarction. These findings support the potential clinical benefits of SGLT2 inhibitors in this patient population. However, interpret the results cautiously because of the small sample size, short follow-up period, single-centre setting, and observational before–after study design without a control group. Larger, multicenter controlled studies with longer follow-up are required to establish long-term cardiovascular benefits.